Navigation Links
Hadasit to Present at the Rodman & Renshaw Annual Global Investment Conference on September 13, 2011
Date:8/31/2011

NEW YORK, Aug. 31, 2011 /PRNewswire/ -- Hadasit Bio-Holdings, Ltd. - (OTCBB: HADSY), a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, announced today that its CEO, Mr. Ophir Shahaf, will present at the Rodman & Renshaw Annual Global Investment Conference in New York City on Tuesday, September 13, 2011 at 12:05 p.m. ET.  The conference will be held at the Waldorf Astoria Hotel.

Investors attending the conference who wish to meet with Mr. Shahaf for a one-on-one meeting should contact their Rodman & Renshaw representative directly.

About Hadasit Bio-Holdings:
Hadasit Bio-Holdings Ltd., established in 2006, is the publicly traded subsidiary of Hadasit Ltd. - the technology transfer company of the Hadassah University Hospital, Israel's foremost medical research center.  The Company was established for the purpose of promoting and commercializing the intellectual property and R&D capabilities generated by Hadassah.

HADSY is the domestically traded ADR of Hadasit Bio-Holdings, a public investment vehicle representing a portfolio of biotech companies, all based on inventions developed at Hadassah.  

Hadasit Bio-Holdings focuses on advancing companies that are past successful preclinical trials and close to completion of Phase I/II clinical trials. The portfolio companies develop drugs with blockbuster potential (markets that are worth over a billion dollars) and operate in the fields of cancer, inflammatory diseases and tissue regeneration using stem cells - areas in which the Hadassah Hospital has extensive knowledge and recognition as a global leader.

For more information please visit: www.hbl.co.il.

Investor Contact
KCSA Strategic Communications
Jeff Corbin / Rob Fink
rfink@kcsa.com
(212) 896-1206


'/>"/>
SOURCE Hadasit Bio-Holdings, Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Clinical Developments at Enlivex Therapeutics - a Hadasit Bio-Holdings Portfolio Company
2. Auxilium Pharmaceuticals to Present at the Morgan Stanley 2011 Healthcare Conference
3. PAREXEL International to Present at Robert Baird Healthcare Conference and William Blair Emerging Growth Stock Conference
4. Life Technologies to Present at the UBS 2011 Global Life Sciences Conference
5. Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September
6. Bacterin International to Present at Stifel Nicolaus 2011 Healthcare Conference on September 8, 2011
7. Amgen Highlights Data to Be Presented at American Society for Bone and Mineral Research Meeting
8. Insmed to Present at 2011 Wedbush Securities Life Sciences Management Access Conference
9. Interleukin Genetics, Inc. to Present at the 2011 Wedbush Securities Life Sciences Management Access Conference
10. Dendreon Announces Webcast Presentation at Canaccord Genuity Growth Conference
11. Omeros to Present at Two Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... (PRWEB) , ... February 08, 2016 , ... ... multilingual testing services, announced today the launch of its revamped and improved website. ... scalable language service solutions, the redesigned website will better communicate how the company ...
(Date:2/9/2016)... ... 2016 , ... PharmApprove announced today the hiring ... for Rare Disorders (NORD). Dorman will lead PharmApprove efforts to work with patients, ... drug regulatory review process. , “Adding Diane Dorman is just the latest in ...
(Date:2/9/2016)... -- BERG, a biopharmaceutical company uncovering health solutions ... the appointment of Jason Haddock as ... brings to BERG over 20 years of experience ... financial functions at pharmaceutical companies, as well as ... Niven R. Narain , BERG,s Chief ...
(Date:2/8/2016)... DELHI , February 8, 2016 ... Invictus Oncology Private Limited, an innovation-driven oncology company ... effective and less toxic, today announced that chairman ... Tata, has invested in the company as part ... financing round, joining existing investors Navam Capital and ...
Breaking Biology Technology:
(Date:1/11/2016)... Synaptics Incorporated (NASDAQ: SYNA ), the ... its ClearPad ® TouchView ™ 4300 touch ... categories in the 8 th Annual Mobile Excellence ... The Synaptics ® TDDI solution enables faster time-to-market, ... devices, brighter displays and borderless designs. ...
(Date:1/8/2016)... Kingdom , Jan. 8, 2016   Bruin Biometrics, ... today announced the closing of a $9 million financing. The ... the financing will be used to accelerate the commercialization of ... early-stage pressure ulcers. United Kingdom ... Mark approval. The device,s introduction has been met with enthusiasm ...
(Date:1/7/2016)... , Jan. 7, 2016 This BCC ... markets for biometric technologies and devices, identifying newer markets ... for various types of biometric devices. Includes forecast from ... Identify newer markets and explore the expansion of ... devices. Examine each type of biometric technology, determine its ...
Breaking Biology News(10 mins):